Literature DB >> 1318411

Expression of the OSU rotavirus outer capsid protein VP4 by an adenovirus recombinant.

M Gorziglia1, A Z Kapikian.   

Abstract

Full-length cDNA of the VP4 gene of porcine rotavirus strain OSU was cloned into adenovirus type 5 (Ad5) downstream of the E3 promoter. The plaque-purified recombinant (Ad5-OSU VP4) expressed apparently authentic VP4 rotavirus outer capsid protein. The protein had the same molecular size (85 kDa) and electrophoretic mobility as did native OSU VP4 and was immunoprecipitated by a polyclonal antiserum raised to OSU VP4. Cotton rats that possessed prechallenge rotavirus antibodies that may have been acquired either passively or actively developed neutralizing antibodies against the OSU strain following intranasal administration of the live Ad5-OSU VP4 recombinant. The neutralizing activity was enhanced by a parenteral booster injection with baculovirus-expressed OSU VP4 antigen. In addition, a high titer of neutralizing antibodies was induced by parenteral administration of the latter antigen and subsequent intranasal administration of the Ad5-OSU VP4 recombinant. These observations indicate that the VP4 outer capsid protein of a rotavirus strain can be expressed by a recombinant adenovirus vector. This approach warrants further exploration for immunization against rotavirus disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318411      PMCID: PMC241248     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

Review 1.  Rotavirus gene structure and function.

Authors:  M K Estes; J Cohen
Journal:  Microbiol Rev       Date:  1989-12

2.  Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen.

Authors:  Y Hoshino; L J Saif; M M Sereno; R M Chanock; A Z Kapikian
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

Review 3.  Development of adenovirus vectors for the expression of heterologous genes.

Authors:  K L Berkner
Journal:  Biotechniques       Date:  1988 Jul-Aug       Impact factor: 1.993

4.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

5.  VP4 protein of porcine rotavirus strain OSU expressed by a baculovirus recombinant induces neutralizing antibodies.

Authors:  K Nishikawa; N Fukuhara; F Liprandi; K Green; A Z Kapikian; R M Chanock; M Gorziglia
Journal:  Virology       Date:  1989-12       Impact factor: 3.616

6.  The nucleotide sequence of the VP3 gene of porcine rotavirus OSU.

Authors:  K Nishikawa; M Gorziglia
Journal:  Nucleic Acids Res       Date:  1988-12-23       Impact factor: 16.971

7.  Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides.

Authors:  E A Emini; B A Jameson; E Wimmer
Journal:  Nature       Date:  1983 Aug 25-31       Impact factor: 49.962

8.  Molecular basis of rotavirus virulence: role of gene segment 4.

Authors:  P A Offit; G Blavat; H B Greenberg; H F Clark
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

9.  Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus.

Authors:  R L Dewar; V Natarajan; M B Vasudevachari; N P Salzman
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

10.  Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters.

Authors:  J E Morin; M D Lubeck; J E Barton; A J Conley; A R Davis; P P Hung
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

View more
  1 in total

1.  Immunogenicity, antigenicity, and protection efficacy of baculovirus expressed VP4 trypsin cleavage products, VP5(1)* and VP8* from rhesus rotavirus.

Authors:  S J Dunn; L Fiore; R L Werner; T L Cross; R L Broome; F M Ruggeri; H B Greenberg
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.